CHICAGO, Jan 8 (Reuters) - The only remaining oral antibiotic used for gonorrhea failed to cure the infection in nearly 7 percent of patients treated at a clinic in Toronto, Canadian researchers said on Monday in the first published study of treatment-resistant gonorrhea in North America.
The study raised alarm among U.S. health officials, who have ordered doctors to stop prescribing the antibiotic known as cefixime because lab cultures showed gonorrhea was starting to develop resistance to the drug.
That left U.S. doctors with only one effective treatment for most cases of gonorrhea, an injectible antibiotic known as ceftriaxone.
"We've been very concerned about the threat of potentially untreatable gonorrhea in the United States," Dr. Gail Bolan, director of the Centers for Disease Control and Prevention's division for sexually transmitted diseases, said in a telephone interview
There have been a number of cases in Europe, but "this is the first time we've had such a report in the actual North American continent," she said. "We feel it's only a matter of time until resistance will occur in the United States."
Until now, signs of antibiotic resistance in North America have been detected mostly through lab tests, which have shown a steady increase in the amount of antibiotic cefixime - marketed by Lupin Ltd as Suprax - that was needed to kill gonorrhea.
"We had seen one case beforehand, but this is the first published report, and it's also the first series of cases in North America," said Dr. Vanessa Allen of Public Health Ontario in Canada, who led the study published in the Journal of the American Medical Association.
Allen and colleagues studied nearly 300 individuals with gonorrhea between May 2010 and April 2011 who were treated with cefixime at a clinic in Toronto, looking for any patients who were still infected during a follow-up visit.
Of the initial 300, 133 returned for retesting. Of those, 13 were still infected, but only nine said they had not had sexual contact that might have reinfected them. That left a failure rate of 6.7 percent.
Allen said the study is a preliminary finding, but still important because it offers some confirmation that people treated with cefixime are not being cured.
It also points out a weakness of newer DNA-based tests commonly used to test for gonorrhea.
Previously, doctors would take fluid samples from patients and grow cultures of gonorrhea bacteria in lab dishes, which could then be used to identify drug resistance. More advanced DNA-based tests, such as nucleic acid amplification tests, cannot be used to test for antibiotic resistance.
"I do think reinvesting in culture-based methodologies is warranted," Allen said, adding that doctors should consider sending patients for retesting to make sure they have been properly treated.
If left untreated, gonorrhea can lead to pelvic inflammatory disease, ectopic pregnancy, stillbirths, severe eye infections in babies and infertility in both men and women.
In the United States, there are approximately 300,000 reported cases of gonorrhea each year. But because infected people often have no symptoms, the actual number of cases is likely closer to 600,000, Bolan said.
So-called "superbug" drug-resistant strains of gonorrhea accounted for almost one in 10 cases of sexually transmitted disease in Europe in 2010, more than double the rate of the year before, health officials from the Stockholm-based European Centre for Disease Prevention and Control said in June.
In addition to closely monitoring for resistance, Bolan said the CDC it is working with its partners at the National Institutes of Health and pharmaceutical companies to encourage the development of new antibiotics and test new combinations of existing drugs.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.